STAGE III HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Clinical trials for STAGE III HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 explained in plain language.
Never miss a new study
Get alerted when new STAGE III HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7 trials appear
Sign up with your email to follow new studies for STAGE III HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Experimental triple therapy takes on head and neck cancer
Disease control OngoingThis early-phase trial tests a new drug called berzosertib (M6620) alongside standard chemotherapy (cisplatin) and radiation in people with advanced head and neck cancer that has spread to nearby tissues. The main goals are to find the safest dose and to see what side effects occ…
Matched conditions: STAGE III HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Could immunotherapy boost radiation for head and neck cancer?
Disease control TerminatedThis study compares standard radiation plus cisplatin against two experimental approaches: radiation with docetaxel and cetuximab, or radiation with cisplatin and the immunotherapy drug atezolizumab. About 613 patients with high-risk stage III-IV head and neck cancer will partici…
Matched conditions: STAGE III HYPOPHARYNGEAL SQUAMOUS CELL CARCINOMA AJCC V7
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC